Interview with Harald Stock, CEO, Grünenthal
You arrived at Grünenthal fairly recently, in January of this year. What was it about the company that attracted you to the position? That goes back to 1987, when I…
Address: Pascalstraße 6
52076 Aachen-Oberforstbach
Germany
Tel: 0.000357327771660262
Web: http://www.grunenthal.de/grt-web/Grunenthal_GmbH_Deutschland/136701132.jsp
Grünenthal is passionate about globally being the preferred partner in pain management for patients, health-care-professionals and payors. The corporation drives innovation to expand European market leadership in moderate to severe pain. Grünenthal is an independent, family-owned German corporation with companies in 34 countries all over the world. Founded in 1946, the corporation employs 2,000 people in Germany and 5,200 worldwide. In 2008, Grünenthal achieved revenues of about 864 million Euros.
Together with highly specialised partners we are pressing on with the research and development of new active substances. For this we are concentrating on selected indications and the latest technological developments. We are intensively searching for innovative ways of improving pain, pain relief and reducing side-effects.
Grünenthal is an independent, family-owned, research-based pharmaceutical company based in Aachen operating internationally. In 1948 Grünenthal was the first German company to manufacture and market penicillin. Today analgesics are our main competence. Beside this Grünenthal is active in the marketing of oral contraceptives and the treatment of respiratory tract diseases.
You arrived at Grünenthal fairly recently, in January of this year. What was it about the company that attracted you to the position? That goes back to 1987, when I…
Roche, once a true pharmaceutical company, is now recognized by its capacity to create a unique business model that allowed to become the world’s largest biotech company with truly differentiated…
Having experienced many years at big pharmaceutical companies, you recently moved into the booming biotech sector by joining Biogen Idec in 2007. What made you make such a decision? The…
Your father was the founder of Dr. Franz Köhler Chemie – that carries his name – and was a very well respected doctor among the German medical and pharmaceutical community.…
Why was the time right in 2000 to start Paion, and how did your background and experiences in the pharma industry, academia and consulting help you create the successful company…
One of the biggest recent milestones for Hikma’s global operations must have been the acquisition of Ribosepharm and Thymoorgan in 2007. How successfully have the two companies integrated into the…
You have a wide professional experience that goes from financial adviser to biotechnology entrepreneur, passing through software business and politics. How will all of those different experiences enable you to…
Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your vision for the company…
Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been…
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
In the last twenty years, Germany has experienced nearly twenty health care reforms. In your opinion, what have been the main reasons for so many changes? The main reason behind…
The DKFZ – German Cancer Research Center – is Germany’s largest cancer research institute with an international recognition recently coroneted with the Nobel Prize to Mr Harald zur Hausen for…
See our Cookie Privacy Policy Here
